with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.

Semaglutide stabilizes epigenetic ageing in people with HIV-associated lipohypertrophy. Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 181, 2025. View the abstract on ...

The following content was published by The Lancet Group and presented at the most recent Conference on Retroviruses and Opportunistic Infections. Don’t miss our content presented at upcoming ...

The phase 2 study – reported at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado – looked at the combination of MSD’s experimental long-acting reverse ...

The study's findings were presented at the Conference on Retroviruses and Opportunistic Infections in March. Researchers are writing up the final results of the study for publication in a ...

The study’s findings were presented at the Conference on Retroviruses and Opportunistic Infections in March. Researchers are currently writing up the final results of the study for publication ...

The CDC has terminated an advisory committee responsible for providing federal guidance on the prevention and control of health care-associated infections ... at the Conference on Retroviruses ...

The study's findings were presented at the Conference on Retroviruses and Opportunistic Infections in March. Researchers are currently writing up the final results of the study for publication in ...

Following an initial announcement of positive results last year, detailed data from the two trials has been presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI).

Diana Walker, The LIFE Images Collection via Getty Images You can see Fauci, circa 1984, on YouTube addressing an AIDS conference ... finally developed an opportunistic infection.

I have received travel grants from ViiV Healthcare and Gilead Sciences to attend the Glasgow HIV Conference 2024 and the Conference on Retroviruses and Opportunistic Infections 2024.